
As a prominent analyst predicts (eventual) drug price controls, biopharma braces for a blow while Trump balls his fist
Sometime this week, no one is sure when, President Donald Trump is expected to give his long-awaited speech on drug pricing. And a long lineup of key players in the field has been scratching their heads, anxiously trying to determine just how far the nation’s most unpredictable president could go.
Trump, of course, has been free with his populist brand of anti-industry rhetoric for more than a year now, after establishing the baseline with repeated assertions that pharma companies have been getting away with murder for years.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.